USPTO Patent Application: Beta-1,3'-galactosyllactose for Gut Barrier Function Diseases
Summary
The USPTO has published a patent application (US20260083764A1) from N.V. Nutricia detailing the use of beta-1,3'-galactosyllactose for treating gut barrier function diseases, particularly in infants and young children. The application was filed on November 24, 2025.
What changed
This document is a USPTO patent application (US20260083764A1) filed by N.V. Nutricia on November 24, 2025. The application claims the use of beta-1,3'-galactosyllactose for improving gut barrier function, specifically for subjects at risk of increased gut barrier permeability, such as infants and young children.
As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on regulated entities. However, it signals potential future developments in the pharmaceutical and food ingredient sectors related to gut health. Companies involved in infant nutrition, functional foods, or pharmaceutical development for gastrointestinal conditions should be aware of this patent filing.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
BETA-1,3'-GALACTOSYLLACTOSE FOR THE TREATMENT OF GUT BARRIER FUNCTION DISEASES
Application US20260083764A1 Kind: A1 Mar 26, 2026
Assignee
N.V. Nutricia
Inventors
Saskia Braber, Belinda Potappel - van 't Land, Selma Paulien Wiertsema, Johan Garssen, Bernd Stahl, Marko Mank
Abstract
The invention relates to the use of beta1,3′-galactosyllactose for improving the gut barrier function. This can in particular be administered to subjects at risk for increased gut barrier permeability, preferably infants and young children.
CPC Classifications
A61K 31/702 A23L 29/04 A23L 29/30 A23L 33/12 A23L 33/125 A23L 33/17 A23L 33/40
Filing Date
2025-11-24
Application No.
19398141
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.